相关实验视频
Updated: Jun 25, 2025

09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.6K
是否由SGLT2抑制剂诱导的GFR下降具有临床意义?
Merve Günes-Altan1,2, Agnes Bosch1, Kristina Striepe1
1Department of Nephrology and Hypertension, University Hospital Erlangen Friedrich-Alexander University Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
Cardiovascular diabetology
|May 29, 2024
概括
-葡萄糖-同载体-2 (SGLT2) 抑制剂可以导致淋巴细胞过率 (GFR) 的初始下降. 这种GFR下降与SGLT2抑制剂治疗的2型糖尿病患者的血管顺应性改善有关.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖-同载体-2 (SGLT2) 抑制剂通常用于2型糖尿病 (T2D).
- 淋巴膜过率 (GFR) 的初始下降是SGLT2抑制剂的已知副作用.
- 这种GFR下降和系统性血管变化之间的关系尚不清楚.
研究的目的:
- 调查SGLT2抑制剂治疗时观察到的初始功能下降是否与全身血管特性变化相关.
- 为了比较基于SGLT2抑制剂的治疗与基于非SGLT2抑制剂的治疗对GFR和血管合规性的影响.
主要方法:
- 在65名T2D患者的12周内测量了真实GFR (mGFR) 和估计GFR (eGFR).
- 患者被随机分配到一种SGLT2抑制剂 (恩帕格利弗洛辛/林格利普丁) 或一种非SGLT2抑制剂 (甲/胰岛素) 治疗方案中.
- 评估脉冲波速度 (PWV) 作为大动脉血管顺应和血压的衡量标准.
主要成果:
- 在SGLT2抑制剂组中,mGFR和eGFR都显著下降,但mGFR变化与eGFR变化没有相关性.
- 在SGLT2抑制剂组的mGFR下降和改善PWV之间发现了显著的相关性,独立于血压变化.
- 在非SGLT2抑制剂组中,没有观察到GFR变化 (mGFR或eGFR) 和PWV变化之间的相关性.
结论:
- 随着SGLT2抑制剂治疗的mGFR初始下降与增加的血管顺应有关,反映了药物对脏和全身血管系统的影响.
- 估计的GFR (eGFR) 可能无法准确地反映SGLT2抑制剂治疗的T2D患者的真正功能变化.
相关概念视频
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Factors Affecting Renal Clearance: Renal Impairment
84
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
84
Glomerular Filtration Rate and its Regulation
2.6K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
2.6K
Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189

